<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Punzalan FER</submitter><funding>Philippine Council for Health Research and Development</funding><pubmed_abstract>&lt;h4>Purpose&lt;/h4>This study was performed to determine the clinical biomarkers and cytokines that may be associated with disease progression and in-hospital mortality in a cohort of hospitalized patients with RT-PCR confirmed moderate to severe COVID-19 infection from October 2020 to September 2021, during the first wave of COVID-19 pandemic before the advent of vaccination.&lt;h4>Patients and methods&lt;/h4>Clinical profile was obtained from the medical records. Laboratory parameters (complete blood count [CBC], albumin, LDH, CRP, ferritin, D-dimer, and procalcitonin) and serum concentrations of cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, IFN-γ, IP-10, TNF-α) were measured on Days 0-3, 4-10, 11-14 and beyond Day 14 from the onset of illness. Regression analysis was done to determine </pubmed_abstract><journal>Frontiers in immunology</journal><pagination>1123497</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10011458</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital.</pubmed_title><pmcid>PMC10011458</pmcid><pubmed_authors>Mondragon AV</pubmed_authors><pubmed_authors>Albay AB</pubmed_authors><pubmed_authors>Mercado MEP</pubmed_authors><pubmed_authors>Avenilla KC</pubmed_authors><pubmed_authors>de Paz-Silava SLM</pubmed_authors><pubmed_authors>Tan JJE</pubmed_authors><pubmed_authors>Alejandria MM</pubmed_authors><pubmed_authors>Aherrera JAM</pubmed_authors><pubmed_authors>David-Wang AS</pubmed_authors><pubmed_authors>Lintao RCV</pubmed_authors><pubmed_authors>Tantengco OAG</pubmed_authors><pubmed_authors>Poblete JB</pubmed_authors><pubmed_authors>Punzalan FER</pubmed_authors><pubmed_authors>Malundo AFG</pubmed_authors><pubmed_authors>Quebral EPB</pubmed_authors><pubmed_authors>Uy MNAR</pubmed_authors><pubmed_authors>Dela Rosa JGL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Utility of laboratory and immune biomarkers in predicting disease progression and mortality among patients with moderate to severe COVID-19 disease at a Philippine tertiary hospital.</name><description>&lt;h4>Purpose&lt;/h4>This study was performed to determine the clinical biomarkers and cytokines that may be associated with disease progression and in-hospital mortality in a cohort of hospitalized patients with RT-PCR confirmed moderate to severe COVID-19 infection from October 2020 to September 2021, during the first wave of COVID-19 pandemic before the advent of vaccination.&lt;h4>Patients and methods&lt;/h4>Clinical profile was obtained from the medical records. Laboratory parameters (complete blood count [CBC], albumin, LDH, CRP, ferritin, D-dimer, and procalcitonin) and serum concentrations of cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, IFN-γ, IP-10, TNF-α) were measured on Days 0-3, 4-10, 11-14 and beyond Day 14 from the onset of illness. Regression analysis was done to determine </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2026-06-03T17:12:47.784Z</modification><creation>2025-04-21T15:06:14.534Z</creation></dates><accession>S-EPMC10011458</accession><cross_references><pubmed>36926338</pubmed><doi>10.3389/fimmu.2023.1123497</doi></cross_references></HashMap>